Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Benzer Materyaller

• Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
  Yazar:: Jung, Hyun Ae, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?
  Yazar:: Hyun Ae Jung, ve diğerleri
  Baskı/Yayın Bilgisi: (2020-10-01)
• Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
  Yazar:: Lee, Jiyun, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
  Yazar:: Yoo, Kwai Han, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)
  Yazar:: Sun, Jong-Mu, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)